Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.

Molecular cancer therapeutics - 1 May 2013

Ninomiya Takashi, Takigawa Nagio, Ichihara Eiki, Ochi Nobuaki, Murakami Toshi, Honda Yoshihiro, Kubo Toshio, Minami Daisuke, Kudo Kenichiro, Tanimoto Mitsune, Kiura Katsuyuki

Abstract excerpt

An irreversible ErbB family blocker is expected to inhibit tumors with activating epidermal growth factor receptor (EGFR) mutations more strongly than reversible EGFR tyrosine kinase inhibitors and to overcome acquired resistance to the T790M secondary mutation. Eleven-week-old transgenic mice with Egfr exon 19 deletion mutation were treated with afatinib, gefitinib, or vehicle for 4 weeks. All mice were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Heterografts

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 23443806
DOI: 10.1158/1535-7163.MCT-12-0885

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.PMID 23443806Read ↗

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.Semantic proximity Read ↗

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.Semantic proximity Read ↗

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.Semantic proximity Read ↗

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Semantic proximity Read ↗

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.Semantic proximity Read ↗

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.Semantic proximity Read ↗

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.Semantic proximity Read ↗

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Semantic proximity Read ↗

Afatinib restrains K-RAS-driven lung tumorigenesis.Semantic proximity Read ↗

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.